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Complexes between C-Reactive Protein and Very Low Density
Lipoprotein Delay Bacterial Clearance in Sepsis
Zhenxing Cheng,* Simon T. Abrams,† Julien Toh,‡ Susan S. Wang,x Colin Downey,{
Xiaoling Ge,† Qian Yu,* Weiping Yu,* Guozheng Wang,*,† and Cheng-Hock Toh†,{
C-reactive protein (CRP) can increase up to 1000-fold in blood and form complexes with very low density lipoproteins (VLDL).
These complexes are associated with worse outcomes for septic patients, and this suggests a potential pathological role in sepsis.
Complex formation is heightened when CRP is over 200 mg/l and levels are associated with the severity of sepsis and blood bacterial
culture positivity. Using a mouse bacteremia model, blood bacterial clearance can be delayed by i.v. injection of CRP–VLDL
complexes. Complexes are more efficiently taken up by activated U937 cells in vitro and Kupffer cells in vivo than VLDL alone.
Both in vitro–generated and naturally occurring CRP–VLDL complexes reduce phagocytosis of bacteria by activated U937 cells.
Fcg and scavenger receptors are involved and a competitive mechanism for clearance of CRP–VLDL complexes and bacteria is
demonstrated. Interaction of phosphocholine groups on VLDL with CRP is the major driver for complex formation and phos-
phocholine can disrupt the complexes to reverse their inhibitory effects on phagocytosis and bacterial clearance. Increased
formation of CRP–VLDL complexes is therefore harmful and could be a novel target for therapy in sepsis. The Journal of
Immunology, 2020, 204: 000–000.
C
-reactive protein (CRP) is an acute phase protein, with
concentrations increasing by up to 1000-fold in sepsis, to
reach circulation levels of 500 mg/l (1) in circulation,
and is used as a diagnostic marker of sepsis (2). High CRP levels
are associated with poor disease outcomes, but the precise
mechanism is poorly understood (3, 4). Although poor clinical
outcomes are related to the severity of the underlying disease,
there remains controversy as to whether CRP plays a protective
or harmful role. The majority of reports have considered CRP as
protective because CRP is involved in the innate immune re-
sponse to activate complement, opsonize pathogens as well as
damaged cells, and cellular breakdown products (5, 6). However,
CRP has been implicated in the development of atherosclerosis
and is regarded as a risk factor for cardiovascular diseases (7–9).
CRP can enlarge the infarct size in a rat model for acute myo-
cardial infarction, and this enlargement is associated with
complement activation (10). Another study has claimed that CRP
has no protective effect on mice challenged with LPS and that
very high CRP levels are associated with poor outcome (11).
High CRP levels in CRP-transgenic mice also cause endothelial
dysfunction (12). These observations suggest that CRP has dual
effects, both protective and harmful, depending on individual
circumstances.
CRP is a calcium-binding protein that exists as a pentamer under
physiological buffer conditions. Phosphocholine (Pch) is the nat-
ural ligand of CRP (13), with CRP binding to apoptotic cells and
certain bacterial strains through this group (5). CRP also binds
oxidized low-density lipoprotein through oxidized phosphatidyl-
choline (14), and this interaction increases oxidized low-density
lipoprotein uptake by macrophages (15). Interactions between
CRP and very low density lipoprotein (VLDL) has been recog-
nized for over two decades (16–18) and is demonstrated in hu-
mans when acute phase serum containing high CRP levels is
incubated with serum from patients with type III to V hyper-
lipoproteinemia (18). No physiological function has been ascribed
to the complex. However, our chance identification of the CRP–
VLDL complex in patients with sepsis by a different clinical in-
vestigative route may provide relevant insight into its function.
When the activated partial thromboplastin time (aPTT) coagula-
tion assay was performed, using an automated optical analyzer,
a phenomenon described as the biphasic waveform was observed
(19). This finding is associated with sepsis and disseminated in-
tracellular coagulation (20) and is caused by interference with
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light transmittance due to increased formation of calcium-dependent
CRP–VLDL complexes (21). This result has now been validated
as a reliable indicator of poor outcome in sepsis (22–24). These
observations suggest that the CRP–VLDL complex may be a
pathological factor in diseases associated with high CRP levels.
Phagocytosis of CRP-opsonized particles, bacteria, and cells
occurs through Fcg I and II receptors (25). These are highly
expressed on macrophages as scavenger receptors and are the
major receptors for clearing modified or aggregated lipoproteins
(26–28). These receptors could therefore be involved in the
clearance of CRP–VLDL complexes, and we hypothesize that the
phagocytic function of macrophages and blood bacterial clearance
in sepsis may be affected if large amounts of CRP–VLDL com-
plexes are present. In this study, we have established an ELISA to
directly quantify circulating CRP–VLDL complexes. We have
found that levels of these complexes in blood were associated with
the severity of sepsis and the positivity of blood bacterial culture.
Using a mouse bacteremia model, we also find that CRP–VLDL
complexes significantly delayed blood bacterial clearance, which
may result from their competitive inhibitory effect on the phago-
cytic function of macrophages. Pch, the head group of phosphati-
dylcholine, is able to efficiently disrupt CRP–VLDL complexes and
reverse the inhibitory effects on bacterial phagocytosis in vitro and
blood bacterial clearance in vivo. Therefore, we speculate that the
CRP–VLDL complex could have potential as a diagnostically-
linkable target for new therapies in sepsis.
Materials and Methods
Patients
Study samples (citrated plasma and serum) were from patients on the
general intensive care unit (ICU) at the Royal Liverpool University Hos-
pital, Liverpool, U.K., diagnosed with severe sepsis and septic shock as
defined by the American College of Chest Physicians/Society for Critical
Care Medicine Consensus Conference Committee (29). This was in ac-
cordance with protocol approved by the Local Research Ethics Committee
(Ref: 07/H1009/64 and 07/H1005/124) and University sponsorship (Ref:
UoL000298), including the recruitment of controls (Ref: RETH000685).
In 2016, the American College of Chest Physicians/Society for Critical
Care Medicine Consensus Conference Committee redefined sepsis and we
have re-examined the clinical records and found that all patients recruited
before 2016 also matched the new sepsis-3 criteria. The demographics of
patients are shown in Supplemental Table I.
Reagents
VLDL, low density lipoprotein (LDL), high density lipoprotein, CRP
(Merck); Pch (TCI Europe); anti-CRP, anti-ApoB (AbD Serotec; Sigma-
Aldrich; Santa Cruz Biotechnology); anti-CD32, CD64, and CD36 (AbD
Serotec); and anti– scavenger receptor A1 (SA1) (R&D Systems) Abs were
purchased. VLDL was isolated from human or mouse serum by ultra-
centrifugation, and CRP was isolated from human ascites (07/H1005/124)
using immobilized p-aminophenyl phosphoryl choline (Pierce) and gel
filtration were monitored using E-TOXATE (Sigma-Aldrich) for LPS
contamination to reach over 95% purity and no detectable LPS. In vitro–
generated CRP–VLDL complexes were prepared by mixing CRP with
VLDL at 1:5 (w/w of protein) ratio in 2.5 mM CaCl2, which was optimized
by gel filtration and monitored by turbidity assay.
Measuring CRP–VLDL complexes using ELISA. Assay design
Immobilization of CRP–VLDL complexes can be achieved using anti-CRP
or ApoB Abs. We have tried both types of assays and found that serum
with very high CRP levels can saturate the CRP binding sites with non-
complexed CRP and thereby mask the real level of CRP–VLDL com-
plexes. In contrast, the circulating levels of VLDL and LDL fluctuate much
less than that of CRP, and using ApoB-coated plates was more appropriate
and accurate. In brief, procedures were as follows: 1:50–1:100 serum di-
lution and anti-CRP–HRP (Abcam, Cambridge, U.K.) 1:12,000 dilution
were used with modified HEPES wash buffer containing 2.5 mM CaCl2 on
anti-ApoB–coated plates. In brief, 8 mg/ml ApoB (AbD Serotec) was
coated on ELISA plates. After blocking with blocking buffer (5% dry milk
in buffer A: 20 mM HEPES [pH 7.4], 100 mM NaCl, 2.5 mM CaCl2), the
plates were incubated with the 1:20–1:100 diluted serum in buffer B
(1% dry milk in buffer A) at room temperature (20–22˚C) for 3 h. After
extensive washing with buffer B, the plates were incubated with 1:10,000
diluted anti-CRP–HRP in buffer B at room temperature for 1 h and then
washed. The chromogen was added and incubated for 15 min and stopped
by adding stop buffer: 0.5 M H2SO4, OD450 nm was measured by a
plate reader. The standard curves were first produced using fresh in vitro–
generated CRP–VLDL complexes as mentioned above. The amount of
CRP–VLDL complexes were represented by the concentration of ApoB in
the complexes. Generation of standard curves was as follows: in vitro–
generated CRP–VLDL complexes were used to generate a standard curve.
The amount of ApoB that complexed with CRP was determined using an
anti-CRP coated plate with a standard curve generated at the same time
using a commercial ApoB kit. The CRP–VLDL standard curve was then
generated by diluting the in vitro–generated CRP–VLDL complexes with a
known concentration of complexed ApoB. With this standard curve, the
concentrations of CRP–VLDL complexes in sera from normal and patients
were determined. Sera with very high levels of CRP–VLDL complexes
were selected and pooled. After determining the concentration of CRP–
VLDL complexes, the pooled serum was aliquoted and stored at 280˚C.
For each assay, the standard curve was generated through a serial dilution
of this pooled serum with known CRP–VLDL concentration. Complexes in
this serum are very stable, at least within a 6 mo period.
aPTT waveform analysis
aPTT waveform analysis was carried out as described in our previous
publication (20). As with previous studies, transmittance level at 18 s
(TL18) was used to quantify the abnormality (,99%), with normal
values $99%.
Mutant CRP proteins
Two mutant CRP proteins were prepared using pET16 (b+) vector (30)
with His-tag removed by factor Xa (Qiagen). Gel filtration ensured
mutant CRP purity (.99%) and that CRP was in pentameric form.
T173A mutant protein was produced as previously described (25).
VLDL and CRP–VLDL uptake
VLDL labeled with Na [125I] using precoated iodination tubes (Pierce) to
achieve 100–200 cpm/ng protein was mixed with VLDL-depleted serum
(1:2). After centrifugation (14,000 rpm, 5 min), one part of the supernatant
was mixed with CRP and the other with an equal volume of buffer. Ac-
tivated U937 cells (using PMA) were incubated with 80 ml basal medium
(without serum), 30 ml mixture (with or without CRP), and 10 ml buffer or
blocking Abs in duplicate 96-well plates, one at 4˚C and the other at 37˚C
for 4 h. After washing with cold PBS, lysed cells (using 0.1 M NaOH)
were g-counted and total protein was measured. VLDL uptake = VLDL
protein/total cell protein at 37˚C – that at 4˚C.
Bacteria clearance assay
C57/BL male mice of average weight (∼22 g) from the Shanghai Labo-
ratory Animal Center/Experimental Animal Centre (Shanghai, China)
were kept at the Research Centre of Gene Modified Mice, State Education
Ministry Laboratory of Developmental Genes and Human Diseases, South-
east University, Nanjing, China. All procedures performed according to state
laws under the license (Jiangsu province, 2151981) and were monitored by
local inspectors. To reduce contamination, BL21 was transfected with
pET16(b+) to gain resistance to ampicillin and then injected into tail veins.
To allow bacterial adaptation to the mouse environment, the cycle of in-
jection–culture–injection was repeated three times prior to formal experi-
ments. Freshly cultured bacteria were suspended in saline, and the amount
equal to ∼50,000 CFU/ml blood at 5 min after injection was given through a
tail vein to each mouse. Twenty microliters of blood was taken through
different veins using heparinized needles/tubes at different time points and
cultured.
Immunohistofluorescent staining
Male C57/BL mice were injected with fluorescent BL21 bacteria, 1 3 105/
mouse, or 200 ml (∼0.5 mg) of FITC-labeled VLDL with or without CRP.
After 4 h, mice were euthanized and liver/spleen fixed with 4% (w/v)
paraformaldehyde for 24 h, then stored in 70% (v/v) ethanol prior to em-
bedding. For staining, 7-mm slices were dewaxed and permeabilized. After
blocking with goat serum (Sigma-Aldrich), anti-CD163 Ab (1:50 dilu-
tion; Santa Cruz Biotechnology) and anti-goat IgG TRICT conjugate
(1:100 dilution; Sigma-Aldrich) were used. Bacteria (green) or VLDL
(green) and Kupffer cells (red) were imaged with an LSM 510 Zeiss
confocal microscope.
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Phagocytosis assay
Escherichia coli, BL21 (Novagen) transformed with pET16b-GFP (.99%
fluorescent) was incubated with PMA-activated U937 cells (20:1 ratio) at
37˚C for 1 h and extensively washed. Cells detached by 0.02% EGTAwere
analyzed using a FACScan flow cytometer (BD Sciences). Percentage of
fluorescent cells was calculated using CellQuest software. Because flow
cytometry could not distinguish phagocytic events from bacterial associ-
ations, a modified phagocytosis assay using eight-well chamber slides was
used. After extensive washing, cells fixed with 4% (w/v) paraformaldehyde
were stained with 10 mg/ml propidium iodide. Bacteria (green) and nuclei
(red) were counted under a fluorescent microscope (1003 objective, 10–20
fields for .200 cells). Phagocytic index, the average bacteria/nucleus, was
calculated. To validate the methodology, confocal microscopy was used to
reconstitute the three-dimensional image of cells and fluorescent bacteria,
demonstrating that over 95% of the bacteria were within the cells (data not
shown).
Statistical analysis
The differences in outcomes between two groups and more than two groups
were assessed using Student t test and ANOVAwith Bonferroni correction,
respectively. In those data that were not normally distributed, median re-
gression were performed. To assess differences in bacterial clearance, we
used the time taken to reach bacterial clearance in each mouse model as
our outcome using negative binomial regression models.
Results
The levels of circulating CRP–VLDL complexes are associated
with the severity of sepsis and blood bacterial culture positivity
The aPTT biphasic waveform reflects formation of CRP–VLDL
complexes through a recalcification process at a calcium con-
centration of ∼8 mM. Evidence for their existence in vivo at
physiological calcium concentrations have been demonstrated
previously (21), but the development of an ELISA has now en-
abled us to quantify their circulating levels. Using serum samples,
CRP–VLDL complexes were detectable in patients with sepsis but
not in healthy donors (Fig. 1A). About 70% of the complexes
could be disrupted by adding 5 mM EGTA (Fig. 1A), indicating
the complexes are calcium dependent. Further evaluation in 67
patients from the ICU showed that levels of CRP–VLDL com-
plexes were associated with the severity of sepsis (Fig. 1B). Pa-
tients with septic shock had significantly higher levels (median
103.8 mg/l, interquartile range [IQR] 65.7, 165.6; n = 25) than
those without shock (median 32.9 mg/l, IQR 21.5, 82.5; n = 21),
nonseptic ICU patients (median 17.9 mg/l, IQR 7.8, 25.8; n = 21),
and healthy donors (median 1.1 mg/l, IQR 0, 4.32; n = 20) (me-
dian regression, p , 0.01) (Fig. 1B). Interestingly, complex levels
were also significantly higher in septic patients with positive blood
bacterial cultures (median 111.7 mg/l, IQR 37.5, 167.7; n = 28)
than those who were negative (49.5 mg/l, IQR 23.4, 75.7; n = 18)
(p , 0.05) (Fig. 1C), suggesting that high levels of circulating
CRP–VLDL complexes may affect blood bacterial clearance.
CRP–VLDL complexes delay bacterial clearance in a mouse
model of bacteremia
To examine if CRP–VLDL complexes could impair blood bacte-
rial clearance, i.v. injection of BL21, a disabled E. coli strain, at
107 CFU/mouse per injection was used with no detectable adverse
effect, and no mice died up to 120 h after injection. When 6 3 104
BL21 bacteria were injected, ∼5 3 104 CFU/ml were found cir-
culating in the blood after 5 min. No living bacteria were detected
in any mouse blood taken at 48 h (Fig. 2A, Supplemental
Table II). Coinfusion of in vitro–generated human CRP–VLDL
complexes (containing 40 mg CRP + 200 mg Apo protein/20 g
body weight [b.w.]) significantly delayed the bacterial clearance
by a factor of 2.1 compared with bacteria alone (incidence rate
ratio [IRR] 2.13: 95% CI; 1.65, 2.73), but no significant effect was
observed when coinfused with VLDL (200 mg protein/20 g b.w.)
(IRR 1.25: 95% CI; 0.96, 1.63). The effect of CRP–VLDL com-
plexes became most apparent at 4 h postinjection with about only
50% of injected bacteria cleared, compared with over 90% in the
bacteria alone group (p , 0.01) (Fig. 2B). Coinfusion with CRP
(40 mg CRP/20 g b.w.) surprisingly shortens the time by ∼25%
compared with bacteria alone (IRR 0.75: 95% CI; 0.56, 0.99),
with CRP levels below 100 mg/l in mouse blood. However, in-
fusion of more CRP to maintain CRP around 100 mg/l did not
significantly alter the time to bacteria clearance (IRR 0.75:
95% CI; 0.52, 1.07) until CRP levels reached 300–400 mg/l,
which significantly delayed bacteria clearance compared with
bacteria alone (IRR 1.88: 95% CI; 1.34, 2.62) (Fig. 2C). Because
human CRP could form complexes with mouse VLDL in vitro and
in vivo (Supplemental Fig. 1A), the delay of bacterial clearance by
infusion high doses of CRP were most likely caused by high levels
of CRP–VLDL complex formation in vivo.
Tissue macrophages take up bacteria and
CRP–VLDL complexes
Using the mouse bacteremia model, GFP-expressing BL21 bacteria
were injected through the tail vein. After 4 h, blood was taken and
the mice were sacrificed. The lungs, kidneys, liver, and spleen were
homogenized and the GFP protein was concentrated using anti-
GFP agarose beads prior to Western blotting (Fig. 3A). GFP
protein was found to be distributed mainly in liver, spleen, and
blood (Fig. 3A). CRP–VLDL significantly reduced liver uptake of
bacteria to increase the extent of circulating bacteria (Fig. 3B,
3C), without significant changes in spleen uptake (Fig. 3D). In
tissue sections, fluorescent bacteria were mainly present in the
liver (Fig. 3Eb), with a few in the spleen and lungs, but not in the
kidneys or white cells in blood smears. This observation supports
previous reports that the liver is the major organ for blood bac-
terial clearance, at least for E. coli (31). When liver sections were
stained using anti-CD163 to highlight Kupffer cells (Fig. 3Ea, d, g),
as demonstrated in Fig. 3Ea–c, bacteria were taken up by Kupffer
cells. Fluorescently labeled CRP–VLDL complexes injected i.v.
were also found to be concentrated in Kupffer cells (Fig. 3Ee, f),
but fluorescently labeled VLDL alone was barely detectable
(Fig. 3Eh, i). This result suggests that tissue macrophages are the
major mechanism by which both blood bacteria and CRP–VLDL
complexes are cleared and that high extracellular levels of these
complexes might delay bacterial clearance by competing for or
affecting phagocytosis, particularly by Kupffer cells.
Phagocytosis of E. coli by PMA-activated U937 cells was
affected by in vitro–generated and naturally occurring
CRP–VLDL complexes
U937 cells induced to differentiate by PMA (32) have been used
as in vitro models to study macrophage function (33). Using
this model to measure the effects of CRP–VLDL complexes on
phagocytosis of bacteria, flow cytometric analysis demonstrated
that ∼50% of activated U937 cells take up fluorescent bacteria
(Fig. 4Aa). Coincubation with isolated VLDL (200 mg/l) had no
significant effect on the percentage of cells taking up bacteria
(526 10%), but in vitro–generated CRP–VLDL complexes (equal
to 40 mg/l CRP and 200 mg/l Apo proteins) significantly re-
duced these numbers (21 6 9%, p , 0.01) (Fig. 4Ab). CRP alone
increased the number of bacteria-containing cells (68 6 12%,
p , 0.05), as reported previously (34) (Fig. 4Ac). Addition of
human serum to the experimental system (up to 25% of the total
reaction volume) demonstrated that those from patients with sepsis,
containing naturally occurring CRP–VLDL complexes, showed
stronger inhibitory effects on phagocytosis of E. coli by activated
U937 cells (23 6 8%) than serum from normal individuals without
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the complexes (56 6 12%, p , 0.01) (Fig. 4Ad). To ensure that the
flow cytometric results reflected bacteria within rather than adhering
to cells, a modified phagocytosis assay using confocal microscopy
was established. Fig. 4B shows a typical image for calculating
phagocytosis index. The average number of bacteria per cell was
measured and a similar result was obtained (Fig. 4C). In vitro–
generated CRP–VLDL complexes and sera from septic patients
significantly reduced the number of bacteria taken up per cell
(p , 0.05), whereas CRP alone significantly increased the
phagocytosis index (p , 0.05). These observations indicate that
CRP–VLDL complexes in blood may inhibit phagocytosis of
bacteria by tissue macrophages.
Fcg and scavenger receptors are involved in the uptake of both
CRP–VLDL and bacteria by PMA-activated U937 cells
As Fcg receptors are involved in the phagocytosis of CRP-opsonized
bacteria or cells (25), we speculated that CRP-opsonized VLDL may
be taken up through a similar mechanism. Based on the aggre-
gative nature of the CRP–VLDL complexes, the scavenger recep-
tors responsible for uptake of modified or aggregated lipoproteins
might also be involved. PMA-activated U937 cells expressing Fcg
II (CD32), FcgI (CD64), SA1, and CD36 (a member of scavenger
receptor B family) (Fig. 5A) were used to evaluate the roles of these
receptors. VLDL uptake by PMA-activated U937 cells was quan-
tified using [125I]-labeled VLDL. To reduce the effect of aggregated
VLDL, which may occur during labeling and purification
processes, [125I]-labeled VLDL was mixed with VLDL-deficient
serum and centrifuged prior to the assay. Activated U937 cells
took up VLDL at a rate of ∼346 6 51 ng lipoprotein/mg cell
protein (mean 6 SD) (Fig. 5B). Once VLDL was mixed with
over 200 mg/l CRP, VLDL uptake was significantly increased
by over 80% after a 4 h incubation (Fig. 5B) (ANOVA test,
p , 0.05). This increase was partially inhibited by adding anti-
CD32 (p , 0.05), anti-CD64 (p , 0.05), or anti-CD36 (p , 0.05)
Abs but not anti-SA1 Ab (Fig. 5C) (p . 0.05). This result indicated
that both Fcg receptors and CD36 are involved. However, VLDL
uptake in the absence of CRP was not significantly affected by
these blocking Abs (p . 0.05) (Fig. 5D). Using our modified
phagocytosis assay, anti-CD32 and anti-CD64 Abs reduced
the rate of phagocytosis significantly (p , 0.05) by 66 and
50%, respectively. Anti-CD36 slightly decreased the rate of
phagocytosis, but with only borderline significance (Fig. 5E)
(p = 0.09), whereas the 25% reduction with anti-SA1 was
significant (p , 0.05). It is therefore likely that CRP–VLDL
complexes compete with bacteria for CD-32 and CD-64 re-
ceptors to affect bacterial clearance.
FIGURE 1. CRP–VLDL complexes exist in the circulation of patients with sepsis. (A) CRP–VLDL complex ELISA of serum samples from patients with
sepsis (n = 3) and normal controls (n = 3), performed in the presence of 2.5 mM CaCl2. In vitro–generated CRP–VLDL complex was used as a positive
control. In some experiments, EGTA (10 mM) was added to samples to chelate calcium and disrupt calcium-dependent CRP–VLDL complexes. CRP–
VLDL complexes were quantified as milligrams per liter of lipoprotein. The mean6 SD from three independent measurements are shown. *p, 0.01 when
compared with normal serum, ⋕p , 0.05 when compared with the same samples without EGTA. (B) CRP–VLDL complex ELISA of serum from healthy
donors (n = 20) and nonseptic ICU (n = 21), septic (n = 21), and septic shock (n = 25) patients. *p , 0.05 when compared with healthy donor group.
(C) CRP–VLDL complex ELISA of septic patients comparing those with positive blood cultures with those whose cultures were negative. *p = 0.029.
FIGURE 2. Bacterial clearance curves in mice. Mice were injected through the tail vein with 60,000 CFU of overnight cultured BL21 bacteria per 20 g
b.w. to achieve ∼50,000 CFU/ml blood, 5 min postinjection. Graph shows mean CFU of time course of blood cultures from at least five mice per group.
(A) Effect of in vitro–generated CRP–VLDL complexes (200 ml containing; 40 mg CRP + 200 mg VLDL/20 g b.w.) on bacterial clearance. For controls,
equal amounts of VLDL or CRP were injected. Total injection volume was no more than 300 ml/20 g b.w. within each 24-h period (estimated to be ,30%
of total blood volume). Bacteria (B) alone: five mice; B+VLDL: seven mice; B+CRP: seven mice; B+CRP–VLDL: 10 mice. (B) Bacterial culture growth of
blood 4 h after bacteria injection. Mean CFU in each group is shown. *p , 0.05 compared with other groups. (C) Effect of 100 or 300–400 mg/l CRP.
Highly concentrated CRP was injected before and 4, 9, 14, and 25 h after bacterial injection to maintain concentrations in mouse blood for more than 24 h.
Bacteria (B) alone: five mice; B+CRP 100 mg: five mice; and B+CRP 400 mg: five mice.
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CRP–VLDL complex is mediated by the Pch moiety
The molecular mechanism underlying formation of the CRP–
VLDL complexes was investigated so as to explore interruption of
CRP–VLDL complexes in functional studies with a view to po-
tential therapeutic strategies. CRP-lipid interactions are calcium
dependent and can be affected by Pch. However, as CRP does not
bind to all types of lipid vesicles and living cells, there is doubt as
to whether this interaction is solely through the hydrophilic head
of phosphatidylcholine. Furthermore, apo-E involvement has also
been reported (18). Site-directed mutagenesis to evaluate the
contribution of the Pch group to the formation of CRP–VLDL
complexes was therefore performed, and the critical amino acids
E66 and E81 in the Pch binding site of CRP protein (35) were
mutated. T173, which is critical for complement binding on the
opposite side of the Pch group binding site (25), was also used as
control. These recombinant proteins were individually added to
normal serum to a concentration of 300 mg/l and compared with
wild-type CRP in their ability to form complexes. The extent of
wild-type CRP in forming CRP–VLDL complexes based on re-
ductions in light transmittance (TL18) was assigned a value of
100%, and the relative capacities of E66A, E81A, and T173A
mutant proteins were 22, 27, and 95%, respectively (Fig. 6A). The
levels of complexes formed with wild-type and mutant CRP were
also measured by ELISA with similar results (Supplemental Fig.
1B). E66A or E81A mutation abolished 70–80% of the capacity
of CRP to form complexes with VLDL. This confirms that the
FIGURE 3. Uptake of bacteria and CRP–VLDL
complexes by Kupffer cells. (A) Western blotting
of relative levels of GFP in blood, liver, spleen,
lungs, and kidneys of mice 4 h after i.v. injection of
GFP-expressing bacteria (B) only and with CRP,
CRP–VLDL, or VLDL, respectively, as described
in Fig. 2A. (B–D) Mean 6 SD of the GFP band
densities of blood (B), liver (C), and spleen (D)
from three independent experiments. *ANOVA test
p , 0.05 compared with bacteria alone, #p = 0.03
when compared with bacteria + CRR–VLDL.
(E) Mice were injected i.v. with GFP-expressing
bacteria, FITC-labeled VLDL, or CRP-FITC-la-
beled VLDL complexes and sacrificed after 4 h.
(Ea–c) Sections from the liver of a mouse injected
with GFP–E. coli, (a) stained with goat anti-mouse
CD163 and anti-goat IgG TRICT conjugate to
highlight Kupffer cells, (b) showing presence of
GFP-E.coli green fluorescence, and (c) merged
images of (a) and (b). Arrows point to the GFP-
bacteria in the Kupffer cells. (Ed–f) Sections from
the liver of a mouse injected with CRP-FITC-la-
beled VLDL complexes, (d) anti-CD163 staining
of Kupffer cells, (e) green fluorescence from in-
jected FITC-VLDL, and (f) merged images of (d)
and (e). (Eg–i) from the liver section of a mouse
injected only with FITC-VLDL with (g) anti-CD163
staining of Kupffer cells, (h) green fluorescence
from FITC-VLDL, and (i) merged images of (g) and
(h). Five mice were used in each treatment group
and typical images are presented. Scale bar, 20 mm.
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interaction of CRP with the Pch moiety is the major mechanism
for forming CRP–VLDL complexes.
Pch can efficiently disrupt CRP–VLDL complexes and reverse
their inhibitory effects on phagocytosis and blood
bacterial clearance
Pch is a natural ligand of CRP and has the strongest affinity among
all known interacting partners of CRP (10). Because Pch is small
and water soluble, it is an ideal competitor of VLDL for the
binding site on CRP. The disrupting effect of Pch was seen from
concentrations as low as 10 mM and was nearly maximal at over
500 mM (Fig. 6B). Over 90% of the in vitro–generated complexes
could be disrupted by 10 mM Pch (Fig. 6B). CRP–VLDL complex
formation in sera from patients with severe sepsis can be easily
visualized by the turbidity change following addition of 8 mM
CaCl2 (Fig. 6C tube B). Addition of 10 mM Pch prevented this
calcium–induced turbidity (Fig. 6C tubes A, C) and also disrupted
pre-existing turbidity or preformed complexes (Fig. 6C tube B).
Furthermore, complex disruption by Pch was not reversed by in-
creasing the concentration of calcium (Fig. 6D) and signifies that
this is not occurring by the same mechanism as EGTA, which
chelates Ca2+. When subsequently centrifuged at 14,000 rpm for
10 min, over 90% of the resultant pellet could be redissolved by
adding 10 mM Pch. The resultant solution contained CRP and
lipoproteins, as determined by mass spectrometry. This result
further confirms that the aPTT-induced turbidity changes as
profiled through the biphasic waveform is a valid method for
detecting aggregated CRP–VLDL complexes.
Pch was also able to abolish the CRP-enhanced uptake of [125I]-
labeled VLDL by PMA-activated U937 cells (Fig. 6E). In the
phagocytosis assay, Pch reversed nearly 80% of the inhibitory
effects of both in vitro–generated and naturally occurring CRP–
VLDL complexes (Fig. 6F). In the mouse bacteremia model, ad-
dition of Pch to the complex before tail vein injection resulted in
dramatic reductions in the levels of CRP–VLDL complexes in
blood (Supplemental Fig. 1C–F). Their inhibitory effects on
bacterial clearance were also significantly reversed (p, 0.05), but
clearance was still delayed compared with the response with
bacteria alone (p , 0.05) (Supplemental Table II), and therefore,
use of Pch still requires further optimization to achieve its maxi-
mum effect. In general, these data indicate a potential for devel-
opment of new therapies using Pch or its homologs for septic
patients with high levels of CRP–VLDL complexes.
Discussion
The clinical significance of CRP–VLDL complexes was seren-
dipitously discovered through an atypical waveform profile in the
aPTT coagulation assay, which turned out to be caused by for-
mation of CRP–VLDL complexes in the plasma of patients with
sepsis (21). The diagnostic and prognostic values of the complexes
have been validated (22–24, 36, 37), and this strong clinical as-
sociation, with close correlation to sepsis progression, suggested
that CRP–VLDL complexes might have a pathological link to
sepsis. Because the biphasic aPTT waveform reflects the induced
aggregation of CRP–VLDL complexes by addition of 8 mM
CaCl2, an ELISA has now been established to enable direct
FIGURE 4. CRP–VLDL complex affects phagocytosis. (A) Flow cytometric analysis showing (a) the effect of PMA activation of U937 cells on bacteria
uptake, (b) bacteria uptake by PMA-activated U937 cells in the absence (red) or presence of CRP (green), (c) the effect of VLDL alone (red) or in complex
with CRP (green) on bacterial uptake, and (d) the effect of 25% sera from patients with sepsis (green) or normal individuals (red) on bacteria uptake. (Ba–c)
Modified phagocytosis assay. Typical image of Phagocytosis of fluorescent bacteria by PMA-activated U937 cells. After incubation of PMA-activated U937
cells with GFP-expressing bacteria, cells were washed extensively and stained with propidium iodide, as described in Materials and Methods. The green
dots are the fluorescent bacteria (GFP), and the red color (propidium iodide) outlines the shape of a cell with a relatively strongly stained nucleus. Scale bar,
20 mm. (C) Using this assay with basal media as a control, the effect of CRP (40 mg/l) or VLDL (200 mg/l) alone or in complex (CPR–VLDL) was tested
alongside 25% sera from normal controls and serum from three patients with severe sepsis (with aPTT biphasic waveform TL18 results of 72%, 92%, and
67%, respectively). Phagocytosis index were calculated as described in Materials and Methods, and mean 6 SD were from at least six independent
experiments. *p , 0.05 compared with control, #p , 0.05 compared with normal serum.
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detection of circulating CRP–VLDL complexes. The correlation
coefficient between the two methods is around 20.6 (p , 0.01).
CRP complexes with purified VLDL, but not LDL and high
density lipoprotein, were detected in the turbidity-based assay
(Supplemental Fig. 2A–C). It is generally believed that CRP
binding to LDL only occurs upon modification (e.g., by oxidation
or immobilization of LDL onto surfaces) (14, 38, 39). Using the
ELISA, low levels of CRP–LDL complexes could be detected
when CRP was incubated with LDL at equal concentrations to
VLDL in the presence of 2.5 mM CaCl2 (Supplemental Fig. 2C).
It is not known if the CRP–LDL complexes detected contained
modified LDL, but it would appear that circulating CRP–VLDL
are predominantly detected by this ELISA.
The association of CRP–VLDL complexes with the severity of
sepsis and their significant correlation with blood bacterial culture
positivity suggests the possibility of a role for these complexes in
blood bacterial clearance. Using a mouse bacteremia model, i.v.
injection of in vitro–generated CRP–VLDL complexes signifi-
cantly delayed bacterial clearance. Furthermore, addition of Pch to
disrupt preformed complexes significantly reduced this inhibitory
effect. Consistent with previous reports that Kupffer cells in the
liver are the major mechanism for removal of bacteria from blood
(31, 40), GFP-labeled bacteria were visualized mainly within
Kupffer cells 4 h after i.v. injection. Of interest, infused FITC-
labeled VLDL alone was not similarly concentrated in Kupffer
cells unless administered in complex with CRP. This would sug-
gest that CRP–VLDL complexes compete with circulating bacteria
for clearance by these tissue macrophages. This inhibitory effect by
in vitro–generated and naturally occurring CRP–VLDL com-
plexes on bacterial phagocytosis was illustrated using PMA-activated
FIGURE 5. Involvement of Fcg and scavenger receptors in the uptake of both CRP–VLDL complexes and bacteria by activated U937 cells. (A) Ex-
pression of Fcg and scavenger receptors in PMA-activated/nonactivated U937 cells. Ten micrograms of cell lysate from nonactivated and activated cells
were subjected to Western blotting using anti-CD36, anti-CD32, anti-CD64, and anti-SA1, respectively. b-Actin served as loading control. (B) Uptake of
soluble [125I] VLDL in VLDL-deficient serum by PMA-activated U937 cells at different CRP concentrations. *p , 0.01 from three independent exper-
iments compared with [125I] VLDL alone. (C) [125I] VLDL-CRP complex uptake or (D) [125I] VLDL uptake in the absence or presence of anti-CD32, anti-
CD64, anti-CD36, and anti-SA1blocking Abs with anti-goat IgG isotype as a control. *p , 0.05 compared with that without [125I] VLDL + CRP alone.
(E) The rate of bacteria phagocytosis by PMA-activated U937 cells was assessed in the presence of anti-CD32, anti-CD64, anti-CD36, anti-SA1, and anti-
goat IgG isotype control Abs. The mean 6 SD from five independent experiments are shown. *p , 0.05 compared with control.
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U937 cells, whereby complex uptake could be blocked in the pres-
ence of Pch, anti-CD32, anti-CD36, and anti-CD64 Abs. These
results indicate that Fcg and scavenger receptors are involved in
CRP–VLDL complex uptake, and, because they are also involved in
bacterial removal, it is likely that CRP–VLDL complexes inhibit
phagocytosis of bacteria by competing for these common re-
ceptors. Another possible explanation is that the CRP–VLDL
complexes are toxic to recipient cells with consequent reduction
in their ability to phagocytose. Such a mechanism of action re-
quires further investigation.
A further finding is that the effect of CRP alone on phagocy-
tosis and blood bacterial clearance can be completely reversed
depending on its concentration. CRP was able to increase the
phagocytic uptake of BL21 bacteria at concentrations from 100 to
300 mg/l in the absence of serum within the culture medium. This
effect was not due to opsonization of bacteria because CRP does
not bind to the bacteria and the effect could not be interrupted by
Pch. It may be that CRP facilitates phagocytosis through activating
Fcg receptors. This effect was shown in the experimental mouse
model whereby 100 mg/l CRP enhanced blood bacterial clearance.
In contrast, CRP concentrations above 300 mg/l significantly re-
duced the efficiency of bacterial clearance. At these concentra-
tions, large amounts of CRP–VLDL complexes were formed
within the circulatory system as detected by ELISA (Supplemental
Fig. 2C), and the inhibitory effect on blood bacterial clearance was
significantly reduced by Pch (Supplemental Table II). These ob-
servations suggest that the inhibitory effects on blood bacterial
clearance rely on the high concentrations of circulating CRP–
VLDL complexes, which form only when CRP levels increased
rapidly and dramatically. This explanation is supported by previ-
ous observations that the aPTT biphasic waveform abnormality
occurs mainly when CRP levels are over 200 mg/l. In a group of
1187 patients admitted to ICU, 44% of the patients with the aPTT
biphasic waveform died compared with 22% of patients without
the abnormality (37). Although patients with the aPTT biphasic
waveform tend to have very high CRP levels (over 200 mg/l), CRP
levels are not well correlated with the degree of the abnormality,
as quantified by the light TL18. Furthermore, the aPTT biphasic
waveform is a much better predictor of sepsis and mortality than
CRP or VLDL alone (23, 37).
Addition of CRP to normal serum also formed CRP–VLDL
complexes, which could be detected by aPTT waveform analysis
and by ELISA (Supplemental Fig. 2D). Complexes before de-
tectable at CRP levels .100 mg/l and increase to reach a plateau
at concentrations of 400 mg/l. This observation could partially
answer the discrepancy between clinical observations and animal
experiments on the protective or harmful effects of CRP. Clini-
cally, CRP can reach 400–500 mg/l in severe sepsis, and such high
levels reflect the severity of the disease and its poor outcome.
However, the protective effects of CRP in Streptococcus pneu-
moniae infection or endotoxemia have been demonstrated in the
majority of reports using CRP transgenic mice (41, 42) or passive
infusion of CRP into mice (43, 44). We also found that CRP could
detoxify circulating histones by direct interaction (6). Under those
FIGURE 6. Effects of CRP mutants and Pch on CRP–VLDL complex formation. (A) The effect of adding 300 mg/l wild-type and mutant CRP proteins
(T173A, E81K, and F66A) to normal serum on CRP–VLDL complex formation, as analyzed by aPTTwaveform assay. The ability of wild-type (wt) CRP to
form the complexes was set at 100% and no CRP [(2) CRP] at 0%. The relative ability (mean6 SD) of each CRP mutant to complex with VLDL in normal
serum from five experiments is shown. *p , 0.05 compared with wt CRP. (B) Effect of 0–10 mM Pch on the complex formation of CRP with isolated
VLDL (artificial, d) or naturally occurring CRP–VLDL complexes (natural, ■) in serum from patients with sepsis. The complexes were measured by
ELISA. Averages from three experiments are plotted against the concentration of Pch added. (C, upper panel) Serum from a patient with sepsis was
aliquoted to test tubes A, B, and C. Pch calcium salt (10 mM), control buffer, and Pch sodium salt (10 mM) were added to test tubes A, B, and C, re-
spectively. Then, CaCl2 was added (8 mM final concentration). (C, lower panel) Pch sodium calcium salt (10 mM) was added to test tube B with the
precipitate disappearing in a few seconds. (D) Turbidity at OD405 nm was measured following the addition of Pch (10 mM). Then, additional CaCl2 (up to
250 mM) was added and the OD405 was determined. Correlation coefficient, r = 0.127, p . 0.05. (E) Effect of Pch (10 mM) on CRP-enhanced uptake
of [125I] VLDL by PMA-activated U937 cells. The relative uptake of [125I] VLDL (mean 6 SD) in presence of Pch and/or CRP are shown (compared
with [125I] VLDL alone, which was set to 100%). *p = 0.012 compared with VLDL alone, ⋕p = 0.038 compared with VLDL + CRP. (F) Effect of Pch
(10 mM) on bacterial phagocytosis by activated U937 cells. The mean 6 SD phagocytosis index without (■) or with Pch (N) from three experiments are
shown. *p , 0.05 compared with the same sample without Pch.
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circumstances, blood CRP levels were around 100 mg/l in the
majority of reported cases (41, 42, 45, 46). As such, there would
have been insignificant amounts of CRP–VLDL complexes in
these animals, and the beneficial effects of CRP would have
predominated.
In a cohort of septic patients, the correlation coefficient, r,
between circulating CRP levels and aPTT TL18, was 20.63
(p , 0.01), and the correlation between CRP and CRP–VLDL
complex detected by ELISA was r = 0.56 (p , 0.01). Although
both these correlations are statistically significant, the r values
indicate that there was not a strong correlation. Through the in-
vestigation of a series of samples from patients with sepsis, we
found that in the recovery phase, normalization of aPTT biphasic
changes did not rely on clearance of CRP (Supplemental Fig. 2E).
In dividing the whole clinical course into an initial phase and a
recovery phase separated by the lowest aPTT TL18 value, the
correlation between CRP and TL18 was improved in the initial
phase (r values from 20.6 to 20.78, p , 0.05) but lost signi-
ficance in the recovery phase (r = 20.32, p . 0.05). If the levels
of CRP in the sera of patients with sepsis as well as in normal
controls were adjusted to 300 mg/l by adding CRP, biphasic
changes were induced in the initial phase and normal control sera
to indicate formation of large amount of complexes. However,
addition of 300 mg/l CRP in the recovery phase serum barely
produced detectable complexes (Supplemental Fig. 2F). Thus,
there may be a natural compensatory mechanism to combat
formation of CRP–VLDL complexes, but its precise nature is as
yet unclear. Therefore, CRP is not a surrogate marker for CRP–
VLDL complexes although high CRP levels are essential for its
formation.
As with other studies, use of human CRP in a mouse model can
be controversial. This is because the mouse system may not fully
represent what happens in humans when high levels of CRP–VLDL
complexes are present. However, because CRP is not an acute
phase protein in mice, levels of CRP in mouse blood are con-
trollable by giving human or rabbit CRP. In addition, human CRP
activates mouse complement (47) and forms complexes with
mouse VLDL (Supplemental Fig. 1A). This is therefore an ideal
system to monitor the effect of CRP–VLDL complexes on bac-
terial clearance through the innate immune system. Of importance
is the observation that the majority of bacteria were cleared by
tissue macrophages (Fig. 3), and this suggests that bacterial killing
in blood by activated complement or other factors was not the
major route for blood bacterial clearance in this animal model.
In this study, Pch was able to completely disrupt the formation of
CRP–VLDL complexes and partially reverse their effects in vitro
and in vivo. In contrast to phosphatidylcholine with its hydro-
phobic fatty acids, Pch is water soluble. Biologically, Pch is an
important intermediate in choline metabolism and membrane lipid
synthesis. In human blood, Pch levels are around 2 mM, but levels
needed to completely disrupt CRP–VLDL complexes in sepsis
were found to be between 200 and 500 mM (Fig. 6B). Levels of up
to 10 mM are not lethal to mice and they reduce the inhibitory
effects of CRP–VLDL complexes on bacterial clearance. As such,
Pch and/or its analogs could potentially be used to disrupt CRP–
VLDL complexes in sepsis.
Although this study provides a biological basis for the clinical
findings of the aPTT waveform in sepsis, a limitation is that
phagocytosis and blood clearance were tested in one E. coli strain
bacteremia mouse model, which does not mean that organ dys-
function would occur and might therefore not be sufficient for the
diagnosis of sepsis in clinical terms. Although the effects of CRP–
VLDL on phagocytosis by macrophages are generic, the ability of
individual bacterial strains to escape phagocytosis or their toxicity
to macrophages and their proliferation rates are different. The
overall effect of CRP–VLDL complexes may therefore vary in
different microbial infections and sepsis with different extent
of organ failure. In addition, the effects of CRP–VLDL may be
different between CRP binding and nonbinding bacterial strains.
For example, CRP directly binds and opsonizes S. pneumoniae
(3, 48), and availability of Pch would enhance the ability of CRP in
complement activation (49) but would interfere with opsonization
of S. pneumoniae. The effect of CRP, CRP–VLDL complexes, and
Pch in this infection could therefore be complicated. The differ-
ential effects of CRP–VLDL complexes and Pch on individual types
of infections will be determined further in future studies.
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10 CRP–VLDL COMPLEXES AFFECT PHAGOCYTOSIS
Key Points
 Kupffer cells phagocytose both bacteria and CRP–VLDL complexes.
 High levels of CRP–VLDL complexes delay bacterial clearance.
 Pch disrupts CRP–VLDL complexes to improve bacterial clearance.
